Medivir AB (MVR0) Price & Analysis

Q: What was Medivir AB’s price range in the past 12 months?

Medivir AB lowest stock price was <€0.01 and its highest was €0.26 in the past 12 months.

Q: What is Medivir AB’s market cap?

Medivir AB’s market cap is €94.94M.

Q: When is Medivir AB’s upcoming earnings report date?

Medivir AB’s upcoming earnings report date is Aug 20, 2026 which is in 28 days.

Q: How were Medivir AB’s earnings last quarter?

Medivir AB released its earnings results on May 05, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.008 by €0.008.

Q: Is Medivir AB overvalued?

According to Wall Street analysts Medivir AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Medivir AB pay dividends?

Medivir AB does not currently pay dividends.

Q: What is Medivir AB’s EPS estimate?

Medivir AB’s EPS estimate is 0.

Q: How many shares outstanding does Medivir AB have?

Medivir AB has 617,939,500 shares outstanding.

Q: What happened to Medivir AB’s price movement after its last earnings report?

Medivir AB reported an EPS of €0 in its last earnings report, beating expectations of -€0.008. Following the earnings report the stock price went down -0.654%.

Q: Which hedge fund is a major shareholder of Medivir AB?

Currently, no hedge funds are holding shares in DE:MVR0

0 Followers

MVR0 Stock Chart & Stats

€0.05

-€0.02(-6.27%)

At close: Jan 08 4:00 PM EST

€0.05

-€0.02(-6.27%)

Day’s Range― - ―

52-Week Range<€0.01 - €0.26

Previous CloseN/A

Volume0.00

Average Volume (3M)176.00

Market Cap

€94.94M

Enterprise Value€1.04K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Aug 20, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding617,939,500

10 Day Avg. Volume530

30 Day Avg. Volume176

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€4.91

Price Target Upside9729.84% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.01

Revenue Forecast (FY)€529.59K

Medivir AB News

Medivir Shareholders Approve Directed Issue to Bolster Drug Development

Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir AB, a Huddinge-based pharmaceutical developer listed on Nasdaq...

3d ago

Medivir secures long-term U.S. patent protection for fostrox–lenvatinib liver cancer combination

The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir AB has secured a Notice of...

3d ago

Medivir Expands Share Capital Following First Tranche of Directed Issue

Medivir AB ( ($SE:MVIR) ) just unveiled an update. Medivir AB has updated its share and vote count...

23d ago

Medivir Files Disclosure Document for Directed Share Issue on Nasdaq Stockholm

Medivir AB ( ($SE:MVIR) ) has issued an announcement. Medivir has prepared and published a disclosure document in...

1M ago

Medivir Calls Extraordinary General Meeting with Expanded Voting Options

Medivir AB ( ($SE:MVIR) ) has shared an announcement. Medivir AB has called an extraordinary general meeting for...

1M ago

Medivir Raises SEK 140 Million to Accelerate MIV‑711 Development in Rare Pediatric Disease

The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir has raised approximately SEK 140 million...

1M ago

Medivir Plans SEK 130 Million Directed Share Issue to Advance Rare Pediatric Disease Drug

Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir plans to raise approximately SEK 130 million through...

1M ago

Medivir’s fostrox combo shows promising liver cancer data in key journal

Medivir AB ( ($SE:MVIR) ) has issued an update. Medivir AB reported that results from a phase 1b/2a...

1M ago

Medivir Begins Key Phase 2 Trial of Fostrox Combo in Advanced Liver Cancer

Medivir AB ( ($SE:MVIR) ) has shared an update. Medivir has announced the enrollment of the first patient...

2M ago

Medivir AGM Backs Board, Extends Capital Mandate and Adopts New Incentive Plan

The latest announcement is out from Medivir AB ( ($SE:MVIR) ). Medivir’s annual general meeting approved the 2025...

3M ago

MVR0 FAQ

What was Medivir AB’s price range in the past 12 months?

Medivir AB lowest stock price was <€0.01 and its highest was €0.26 in the past 12 months.

What is Medivir AB’s market cap?

Medivir AB’s market cap is €94.94M.

When is Medivir AB’s upcoming earnings report date?

Medivir AB’s upcoming earnings report date is Aug 20, 2026 which is in 28 days.

How were Medivir AB’s earnings last quarter?

Medivir AB released its earnings results on May 05, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.008 by €0.008.

Is Medivir AB overvalued?

According to Wall Street analysts Medivir AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medivir AB pay dividends?

Medivir AB does not currently pay dividends.

What is Medivir AB’s EPS estimate?

Medivir AB’s EPS estimate is 0.

How many shares outstanding does Medivir AB have?

Medivir AB has 617,939,500 shares outstanding.

What happened to Medivir AB’s price movement after its last earnings report?

Medivir AB reported an EPS of €0 in its last earnings report, beating expectations of -€0.008. Following the earnings report the stock price went down -0.654%.

Which hedge fund is a major shareholder of Medivir AB?

Currently, no hedge funds are holding shares in DE:MVR0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medivir AB

Medivir AB is pharmaceutical research and development company. It develops pharmaceuticals for the treatment of cancer and specializes in protease inhibitor research and nucleotide science. The firm conducts research in all phases of pharmaceutical development from idea to clinical phase III studies. Its project pipeline includes Remetinostat, MIV-711, Birinapant, MIV-818, MIV-323 proprietary projects and also Olysio, JNJ-4178, Xerclear and MIV-802 partnership projects. The firm's products include Xerclear and Simprevir.

Medivir AB (MVR0) Earnings & Revenues

Historic Earnings Reports

MVR0 Stock 12 Month Forecast

Average Price Target

€4.91

▲(9729.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","5":"€5","-1":"-€1","0.5":"€0.5","3.5":"€3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.914918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€4.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.914918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.914918,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2022","6":"Aug<br/>2022","9":"Feb<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.126,0.4943783076923077,0.8627566153846153,1.2311349230769228,1.5995132307692308,1.9678915384615383,2.336269846153846,2.7046481538461538,3.0730264615384613,3.4414047692307688,3.8097830769230767,4.178161384615385,4.546539692307692,{"y":4.914918,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.126,0.4943783076923077,0.8627566153846153,1.2311349230769228,1.5995132307692308,1.9678915384615383,2.336269846153846,2.7046481538461538,3.0730264615384613,3.4414047692307688,3.8097830769230767,4.178161384615385,4.546539692307692,{"y":4.914918,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.126,0.4943783076923077,0.8627566153846153,1.2311349230769228,1.5995132307692308,1.9678915384615383,2.336269846153846,2.7046481538461538,3.0730264615384613,3.4414047692307688,3.8097830769230767,4.178161384615385,4.546539692307692,{"y":4.914918,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.592,"date":1614556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.592,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.592,"date":1635724800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.592,"date":1643673600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.592,"date":1648771200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.584,"date":1654041600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.598,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.228,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.113,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.126,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >